Home Biosimilar Antibodies Others Others Rozanolixizumab (Anti-FcRn (FCGRT & B2M))
For research use only. Not for use in humans.

Rozanolixizumab (Anti-FcRn (FCGRT & B2M))

Synonyms: UCB7665

Rozanolixizumab (Anti-FcRn (FCGRT & B2M)) is a high-affinity humanized monoclonal antibody, targeting human neonatal Fc receptor (FcRn) and is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases. MW: 150 KD.

Rozanolixizumab (Anti-FcRn (FCGRT & B2M))

Quality Control

Batch: A250001 Purity: 99% Protein concentration: 4.06mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Rozanolixizumab (Anti-FcRn (FCGRT & B2M)) is a high-affinity humanized monoclonal antibody, targeting human neonatal Fc receptor (FcRn) and is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases. MW: 150 KD.

Product Details

CAS No. 1584645-37-3
Molecular Weight 150 kDa
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.